Complete remission of IgA nephropathy after bone marrow transplantation for acute myeloid leukaemia

Eun-Kyung Park; Jin-Seok Jeon; Hyun-Jin Noh; Jong-Ho Won; Hee-Sook Park
December 2008
NDT Plus;Dec2008, Vol. 1 Issue 6, p420
Academic Journal
IgA nephropathy is the most common primary glomerulonephritis, but the pathogenesis of IgA nephropathy is still unclear. A 32-year-old woman was found to have IgA nephropathy and acute myeloid leukaemia. She was treated with allogenic bone marrow transplantation (BMT). After BMT, immunoflourescent staining of IgA and proteinuria disappeared. These findings suggest bone marrow cells are involved in the pathogenesis of IgA nephropathy. We herein report a case of complete remission of IgA nephropathy after BMT for acute myeloid leukaemia.


Related Articles

  • Roles of bone marrow cells in glomerular diseases. Imasawa, Toshiyuki // Clinical & Experimental Nephrology;Sep2003, Vol. 7 Issue 3, p179 

    Bone marrow transplantation (BMT) has been used as a tool to investigate various roles of bone marrow cells in glomerular diseases. BMT from IgA nephropathy-prone mice caused glomerular IgA deposition associated with increased circulating macromolecular IgA in normal recipients. Conversely,...

  • Th1 polarization in murine IgA nephropathy directed by bone marrow-derived cells.  // Kidney International;Nov2011, Vol. 80 Issue 9, p1000 

    A correction to the article "Th1 polarization in murine IgA nephropathy directed by bone marrow-derived cells" that was published in the 2011 issue is presented.

  • Allogeneic bone marrow transplantation improves the outcome of de novo AML with trilineage dysplasia (AML-TLD). Taguchi, J; Miyazaki, Y; Yoshida, S; Fukushima, T; Moriuchi, Y; Jinnai, I; Matsuo, T; Kuriyama, K; Tomonaga, M // Leukemia (08876924);Nov2000, Vol. 14 Issue 11, p1861 

    De novo acute myeloid leukemia (AML) with dysplastic features in erythroblasts, granulocytes and megakaryocytes, similar to those in myelodysplastic syndrome (MDS) has been described as AML with trilineage dysplasia (AML-TLD) since 1987. Several reports have suggested that AML-TLD is a subtype...

  • "A STRANGER SAVED MY LIFE".  // Dolly;Feb2014, Issue 518, p82 

    A personal narrative is presented which explores the author's experience of how an anonymous bone marrow donor helped her in surviving acute myeloid leukaemia (AML).

  • Treatment of Acute Myelogenous Leukemia . Champlin, Richard E.; Ho, Winston G.; Gale, Robert Peter; Winston, Drew; Selch, Michael; Mitsuyasu, Ronald; Lenarsky, Carl; Elashoff, Robert; Zighelboim, Jacob; Feig, Stephen A. // Annals of Internal Medicine;Mar85, Vol. 102 Issue 3, p285 

    Deals with a study which assessed the relative effectiveness of allogeneic bone marrow transplantation and postremission chemotherapy for adult patients with acute myelogenous leukemia in first complete remission. Methods used in the study; Results and discussion.

  • Allogeneic blood stem cell and bone marrow transplantation for acute myelogenous leukemia and myelodysplasia: influence of stem cell source on outcome. Russell, J. A.; Larratt, L.; Brown, C.; Turner, A. R.; Chaudhry, A.; Booth, K.; Woodman, R. C.; Wolff, J.; Valentine, K.; Stewart, D.; Ruether, J. D.; Ruether, B. A.; Klassen, J.; Jones, A. R.; Gyonyor, E.; Egeler, M.; Dunsmore, J.; Desai, S.; Coppes, M. J.; Bowen, T. // Bone Marrow Transplantation;12/1/99, Vol. 24 Issue 11, p1177 

    We have compared the outcomes of 87 patients with acute myelogenous leukemia (AML) and myelodysplasia (MDS) receiving matched sibling transplants with stem cells from peripheral blood (blood cell transplant, BCT) or bone marrow (BMT). In good risk patients (AML in CR1) granulocytes recovered to...

  • Allogeneic bone marrow transplantation for childhood leukemia following a busulfan and melphalan preparative regimen. Matsuyama, T.; Kojima, S.; Kato, K. // Bone Marrow Transplantation;7/1/98, Vol. 22 Issue 1, p21 

    Thirty children with leukemia underwent allogeneic bone marrow transplantation (BMT) following a radiation-free preparative regimen, from July 1988 to January 1996. Twelve males and 18 females, ages 9 months to 15 years (median 8.5 years), received busulfan (BU, 4 mg/kg/day for 4 days by mouth),...

  • Donor cell-derived acute myeloid leukemia developing 14 months after matched unrelated bone marrow transplantation for chronic myeloid leukemia. Hambach, L; Eder, M; Dammann, E; Battmer, K; Stucki, A; Heil, G; Ganser, A; Hertenstein, B // Bone Marrow Transplantation;10/1/2001, Vol. 28 Issue 7, p705 

    We report a patient with Ph-positive CML who developed a Ph-negative AML in donor cells 14 months after BMT from an HLA-identical male unrelated donor. The Ph translocation could not be detected by either conventional cytogenetics, FISH or RT-PCR analysis excluding relapse of CML in myeloid...

  • High incidence of extramedullary relapse of AML after busulfan/cyclophosphamide conditioning and allogeneic stem cell transplantation. Simpson, D R; Nevill, T J; Shepherd, J D; Fung, H C; Horsman, D E; Nantel, S H; Vickars, L M; Sutherland, H J; Toze, C L; Hogge, D E; Klingemann, H G; Naiman, S C; Barnett, M J // Bone Marrow Transplantation;8/1/98, Vol. 22 Issue 3, p259 

    While allogeneic stem cell transplantation (SCT) is curative for a significant number of patients with AML, relapse of disease within the bone marrow and/or extramedullary (EM) sites following high-dose therapy continues to limit the success of this treatment. Between October 1985 and December...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics